Efficacy and safety of Eslicarbazepine acetate as preventive therapy for patients with migraine: a double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial.

Trial Profile

Efficacy and safety of Eslicarbazepine acetate as preventive therapy for patients with migraine: a double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Migraine with aura; Migraine without aura
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 May 2014 Tolerability results from a pooled analysis of 5 trials in elderly patients who participated in non-epilepsy studies presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 29 Apr 2013 Status changed from recruiting to completed.
    • 02 Aug 2011 This trial is recruiting in Spain, but completed in Austria, Bulgaria, Czech Republic, Germany, Italy, Lithuania and Portugal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top